Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Aug;5(Suppl 2):S253-S256.
doi: 10.21037/tcr.2016.08.12.

HNF1A, KRT81, and CYP3A5: three more straws on the back of pancreatic cancer?

Andrew J Scott  1 , John C Wilkinson  1
Affiliations
Comment

HNF1A, KRT81, and CYP3A5: three more straws on the back of pancreatic cancer?

Andrew J Scott et al. Transl Cancer Res. 2016 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Mechanism of CYP3A5-mediated basal and acquired therapy resistance among PDAC subtypes. In exocrine-like tumors, basal expression of CYP3A5 is regulated by HNF4A while drug-induced expression is mediated by NR1I2/PXR. Classical and QM-PDA tumors may acquire drug resistance via upregulation of CYP3A5 following sustained treatment. CYP3A5, cytochrome P450 3A5.
See this image and copyright information in PMC

Comment on

  • CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
    Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. Noll EM, et al. Nat Med. 2016 Mar;22(3):278-87. doi: 10.1038/nm.4038. Epub 2016 Feb 8. Nat Med. 2016. PMID: 26855150 Free PMC article.

References

    1. Kelly CM, Buzdar AU. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer. Drugs 2013;73:505–15. - PubMed
    1. Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015;21:9297–316. - PMC - PubMed
    1. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500–3. - PMC - PubMed
    1. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 2015;47:1168–78. - PMC - PubMed
    1. Noll EM, Eisen C, Stenzinger A, et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278–87. - PMC - PubMed